Announcements Trials
Browse Landscape

Phase

Phase 3 13Phase 2 9Phase 1/2 4Phase 1 4Phase NA 1Phase 2/3 1

Status

Completed 4

Sponsor Class

OTHER 8INDUSTRY 4NIH 1INDIV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Classical hematology 1

Conditions

Tissue Adhesions 1Pancreatic Neoplasms 1Neutropenia 1Neoplasms 1Myoma 1Febrile Neutropenia 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Sodium Chloride × Clear all
NCT01453153 2018-11-30

Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

Halozyme Therapeutics

Phase 1/2 Completed
28 enrolled 31 charts
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT01619423 2018-07-06

PLIANT

Egetis Therapeutics

Phase 1/2 Completed
186 enrolled 12 charts
Classical hematologyGastrointestinal

Neutropenia, Colorectal Neoplasms, Febrile Neutropenia

NCT00960115 2015-10-21

Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
178 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02166554 2014-06-18

BAP

BioRegen Biomedical (CHangzhou) Co., Ltd

Phase 1/2 Completed
216 enrolled

Tissue Adhesions, Myoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡